| Document |
Document Title |
|
WO/2022/188903A1 |
The present disclosure relates to 3'3' cyclic dinucleotides containing isonucleotidic units, their pharmaceutically acceptable salts, their pharmaceutical composition and combinations of said substances and other medicaments or pharmaceu...
|
|
WO/2022/187312A1 |
The present disclosure provides a process of separating designated oligomeric compounds from sample solutions comprising at least one contaminant. In certain embodiments, the designated oligomeric compounds comprise a modified oligonucle...
|
|
WO/2022/183281A1 |
Among other things, in general, compositions and methods of treatment for muscular dystrophy and other diseases are disclosed. A method of treatment of a subject is disclosed, in which fatty acid utilization is improved. The method inclu...
|
|
WO/2022/182604A1 |
The invention relates to compounds of Formula (I), salts thereof, pharmaceutical compositions thereof, as well as methods of treating or preventing HIV in subjects.
|
|
WO/2022/183066A1 |
The present application is directed to, in part, nucleotide analogs with a novel design of a 3'-OH reversible terminator that comprises an enzyme-cleavable linkage.
|
|
WO/2022/183109A1 |
An electroporation buffer comprising: a solvent; a sugar; a chloride salt; and a buffering agent. In certain embodiments: the solvent is water; the sugar is glucose or mannitol; the chloride salt is potassium chloride (KCl) or magnesium ...
|
|
WO/2022/175685A1 |
The present invention relates to a compound according to Formula (la) or (lb) wherein R1; R3; Y and X are defined herein, and their use in methods of nucleic acid synthesis. Disclosed herein is a method of reducing the deamination of the...
|
|
WO/2022/174351A1 |
Novel and known substituted purine compounds and salts thereof act as adenosine A2a receptor (A2aR) antagonists for cancer immunotherapy, depression, anxiety, multiple sclerosis, NASH, scleroderma, ADHD, Alzheimer's and Parkinsons. Pharm...
|
|
WO/2022/175684A1 |
The present invention relates to a compound according to Formula (1a) or (1b): wherein R1; R2; R3 X and Y are defined herein, and their use in methods of nucleic acid synthesis.
|
|
WO/2022/171561A1 |
The present invention relates to a D-galactopyranose compound of formula (1) wherein the pyranose ring is beta-D-galactopyranose, and these compounds are high affinity galectin-1 and/or 3 inhibitors for use in treatment of inflammation; ...
|
|
WO/2022/174194A1 |
Disclosed are halogen containing nucleotide and nucleoside therapeutic compositions and uses related thereto. In certain embodiments, the disclosure relates to the treatment or prophylaxis of viral infections. Such viral infections can i...
|
|
WO/2022/168106A1 |
Disclosed herein is a process for synthesis of Molnupiravir from cytidine of using a lipase for esterification reaction. The process comprises of reacting compound of formula II with acetone in presence of sulphuric acid to obtain compou...
|
|
WO/2022/168107A1 |
Disclosed herein is the enzymatic process for synthesis of Molnupiravir intermediate, 5'-isobutylester of cytidine acetonide. The process employs cytidine acetonide as starting material to prepare 5'-isobutylester of cytidine acetonide. ...
|
|
WO/2022/166581A1 |
A nucleotide derivative, a pharmaceutical composition thereof, and a use thereof. Specifically disclosed are a nucleotide derivative represented by formula (I) or a tautomer, a stereoisomer, a solvate, a pharmaceutically acceptable salt ...
|
|
WO/2022/163764A1 |
Provided is a method for producing an imidazopyridine derivative represented by formula (I), wherein, in formula (I), X is H, a substituted or unsubstituted propenyl group, a substituted or unsubstituted propinyl group, or a substituted ...
|
|
WO/2022/165358A1 |
A process is provided for microencapsulating nicotinamide riboside (NR), and other NR derivatives by using ethyl cellulose which may be polymerized in a particular manner. Further, compositions comprising NR or derivatives thereof microe...
|
|
WO/2022/164941A1 |
Advantageous isolated morphic Form III of the hemi-sulfate salt of AT-527 that exhibits a faster rate of dissolution over the amorphous form leading to increased bioavailability and thus efficacy for therapeutic administration in a solid...
|
|
WO/2022/163846A1 |
The purpose of the present invention is to provide: a novel stereoselective method for producing a cyclic dinucleotide derivative that can be used for an antibody-immunostimulator conjugate; and a production intermediate thereof. Another...
|
|
WO/2022/159872A1 |
Disclosed herein are adenosine derivative prodrugs and compositions thereof that can be used for the treatment of HIV infection or RNA virus infection.
|
|
WO/2022/159877A1 |
The present disclosure is directed to methods of treating or preventing RNA virus infections and retroviral diseases, such as HIV and AIDS, comprising administering to a subject in need an effective amount of (a) a capsid inhibitor and (...
|
|
WO/2022/159811A1 |
This invention provides compounds of Formulae (I), (IA), (IB), (IC), (ID), (IE), (IF), (IG), (IH), (IJ), (II), (III), (IIIA), and (IIIB); pharmaceutically acceptable salts and solvates thereof; and compositions thereof. This invention fu...
|
|
WO/2022/157173A1 |
The present invention relates to methods of making a nicotinamide ribofuranoside salt, in particular a crystalline nicotinamide ribofuranoside salt, via salt metathesis comprising subjecting nicotinamide ribofuranoside hydrogen malate or...
|
|
WO/2022/147223A2 |
This invention relates to an oligonucleotide comprising one or more 2'-modified nucleosides, wherein the 2'-position of the nucleoside has a structure of formula (I). The invention also relates to a pharmaceutical composition comprising ...
|
|
WO/2022/143740A1 |
Provided are a compound having both regulatory or agonist effects on adenosine A3 receptor activity, a method for preparing the series of compounds, a pharmaceutical composition of the series of compounds, and the medical use of the seri...
|
|
WO/2022/140365A1 |
Provided herein, are compositions comprising GalNAc moieties that may be conjugated to an oligonucleotide. The oligonucleotide may be a small interfering RNA or an antisense oligonucleotide. Also provided herein are methods of treatment ...
|
|
WO/2022/133205A1 |
The present invention relates to efficient synthetic processes useful in the preparation of antiviral nucleosides, particularly uridine 4-oxime 5'-(2-methylpropanoate) {(2R,3S,4R,5R)-3,4-dihydroxy-5-[4-(hydroxyimino)-2-oxo-3,4-d
ihydropy...
|
|
WO/2022/127914A1 |
The invention concerns compounds of formula (I) which modulate, especially agonize alpha kinase 1 (ALPK1) and are useful for treating a condition, disease or disorder in which a decrease or increase in ALPK1 activity contributes to the p...
|
|
WO/2022/127920A1 |
Provided in the present invention are a preparation method for and an intermediate of a 5'-nucleoside prodrug. Specifically, provided in the present invention is a method for preparing a compound of formula VI. The method comprises the s...
|
|
WO/2022/131350A1 |
The purpose of the present invention is to overcome problems in the acquisition of a DNA aptamer in the conventional methods, including the lack of variety of interactions with target molecules, the increase in the cost for aptamer acqui...
|
|
WO/2022/129930A1 |
The present application relates to alkylpyridinium substituted coumarin dyes of formula (I) and their uses as fluorescent labels. For example, these dyes may be used to label nucleotides for nucleic acid sequencing applications. wherein ...
|
|
WO/2022/123432A1 |
Provided herein are compositions for use in treatment of cancer comprising a therapeutically effective amount of harmine or a pharmaceutically acceptable salt thereof in combination with a therapeutically effective amount of cordycepin. ...
|
|
WO/2022/123501A1 |
The invention provides compounds of the Formula (I) or the Formula (Ia) which are useful intermediates in the synthesis of potential antiviral drugs such as 3'-deoxy-3',4'-didehydro-cytidine triphosphate (ddhCTP).
|
|
WO/2022/125735A1 |
The disclosure provides processes for preparing the compound of formula (VIII) and pharmaceutically acceptable salts thereof. Intermediates useful in preparing the compound of formula (VIII) are also provided.
|
|
WO/2022/124410A1 |
Provided are cytosine-type crosslinked nucleoside amidite crystals represented by a structural formula. In the formula, R2 and R2 are substitution groups and R3 is a protector group.
|
|
WO/2022/125031A1 |
The invention relates to trimethyl chitosan nanoparticles containing magnetic -targeted gemcitabine developed for use in the treatment of lung cancer.
|
|
WO/2022/119784A1 |
5' -O-Phenylacetyluridine effectively delivers both phenylacetate and uridine to a subject. It can be used to treat hepatic encephalopathy and genetic disorders of the hepatic nitrogen cycle.
|
|
WO/2022/109741A1 |
CD73 (also known as ecto-5´-nucleotidase) inhibitor compounds are provided, as well as compositions and uses thereof for treating or preventing CD73-associated or related diseases, disorders and conditions, including cancer- and immune...
|
|
WO/2022/114105A1 |
The present invention addresses the problem of a providing NMN having high purity and a low impurity content. The present invention is a high-purity β-nicotinamide mononucleotide (NMN) which has a purity of 99.0 mass% or higher and in...
|
|
WO/2022/109551A1 |
The present invention relates to compounds and methods useful for inhibiting non-receptor tyrosine-protein kinase Src ("Src"). The invention also provides pharmaceutically acceptable compositions comprising compounds of the present inven...
|
|
WO/2022/109244A1 |
Thymidine analogues, 5-substituted 2'-deoxy-2'-[18F]fluoro-arabinofuranosyluracil derivatives, are promising positron emission tomography (PET) tracers being evaluated for noninvasively imaging cancer cell proliferation and/or reporter g...
|
|
WO/2022/104154A1 |
The invention features a method of treating a disease or disorder in a subject, the method comprising administering a therapeutically effective amount of a 5'-tiRNA to treat the disease or disorder in the subject.
|
|
WO/2022/098757A1 |
Provided are HSD17B13 substrates, reaction products, kits, and methods that include the HSD17B13 substrates or reaction products of the HSD17B13 substrates. Some embodiments include methods of treatment. Some such embodiments include det...
|
|
WO/2022/098371A1 |
This instant invention provides compounds that inhibit viruses of the Coronaviridae family. This invention also comprises compounds that inhibit viral nucleic acid polymerases, particularly SARS-CoV-2 RNA-dependent RNA polymerase (RdRp),...
|
|
WO/2022/089612A1 |
Use of a uridine derivative in preparation of a medicament. The medicament is used for preventing or treating a limb disease associated with administration of a chemotherapy drug in a subject. Further provided is a pharmaceutical combina...
|
|
WO/2022/083686A1 |
A modified nucleoside or nucleotide, the 3'-OH of the modified nucleoside or nucleotide being reversibly blocked; meanwhile, the present invention also relates to a kit comprising the nucleoside or nucleotide, and a sequencing method bas...
|
|
WO/2022/086958A1 |
Provided herein are nucleotide prodrug compounds, their preparation and their uses, such as treating diseases or conditions of a viral infection.
|
|
WO/2022/084331A2 |
The present disclosure provides novel piperidine- and guanosine-derived ligands that bind specifically to asialoglycoprotein receptor (ASGPR) and nucleotide analogs conjugated thereto that can be incorporated into oligonucleotides, inclu...
|
|
WO/2022/081739A1 |
Provided are compounds of Formula (I') or (I) below, or pharmaceutically acceptable salts thereof, and methods for their use and production.
|
|
WO/2022/081973A1 |
Compounds and methods of using said compounds, alone or in combination with additional agents, and pharmaceutical compositions of said compounds for the treatment of viral infections are disclosed.
|
|
WO/2022/074391A1 |
The present invention relates to compounds of formula (I) that function as inhibitors of METTL3 (N6-adenosine-methyltransferase 70 kDa subunit) enzyme activity: W-X-Y-Z (I) wherein X, Y and Z are each as defined herein. The present inven...
|
